rilzabrutinib: a novel promising btk inhibitor being explored in itp
Published 1 year ago • 484 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:21
the potential of adding anti-cd20 antibodies to acalabrutinib and venetoclax in cll
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:41
developing novel gene therapy approaches for hemoglobinopathies
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
21:04
showcase biosurveillance
-
14:24
the theory of everything
-
2:41
israeli company on the edge of finding diabetes cure
-
1:47
shared treatment decision-making
-
0:48
b-cell receptor signaling proteins as biomarkers of progression in cll
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
4:57
a potential novel hemophilia treatment: an in vitro study of eptacog beta and emicizumab
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:21
overview of the role of non-covalent btk inhibitors in the era of covalent btk inhibitors
-
2:24
judging the value of a clinical trial in hem-onc